Dissecting the Role of Single Regions of an IAPP Mimic and IAPP in Inhibition of Aβ40 Amyloid Formation and Cytotoxicity

Alzheimer's disease (AD) and type 2 diabetes (T2D) are linked to the self‐association of β‐amyloid peptide (Aβ) and islet amyloid polypeptide (IAPP), respectively. We have shown that IAPP‐GI, a soluble IAPP analogue and mimic of nonamyloidogenic and nontoxic IAPP, binds Aβ with high affinity and blocks its cytotoxic self‐assembly and fibrillogenesis. We have also shown that IAPP and Aβ interact with each other into nonfibrillar and nontoxic heterocomplexes that suppress cytotoxic self‐association by both polypeptides. The Aβ–IAPP interaction might thus be a molecular link between AD and T2D. We studied the role of individual IAPP‐GI and IAPP regions in their inhibitory function on Aβ40 self‐association and cytotoxicity. We found that the presence of the two hot‐spot regions of the Aβ–IAPP interaction interface in IAPP(8–28) is not sufficient for inhibitory function and that, in addition to IAPP(8–28), the presence of the N‐terminal region IAPP(1–7) is absolutely required. By contrast, the C‐terminal region, IAPP(30–37), is not required although its presence together with IAPP(1–7) in IAPP‐GI results in a marked enhancement of the inhibitory effect as compared to IAPP(1–28)‐GI. We suggest that the inhibitory effect of IAPP‐GI and IAPP on Aβ40 fibrillogenesis and cell toxicity is mediated primarily by interactions involving the hot regions of the Aβ–IAPP interaction interface and the N terminus of IAPP while a concerted and likely structure‐stabilizing action of the N‐ and C‐terminal IAPP regions potentiates this effect. These results identify important molecular determinants of the amyloid suppressing function of the Aβ40–IAPP interaction and could contribute to the design of novel inhibitors of Aβ40 aggregation and cell degeneration.

[1]  Hong Qing,et al.  Beta amyloid and hyperphosphorylated tau deposits in the pancreas in type 2 diabetes , 2010, Neurobiology of Aging.

[2]  R. Raffa,et al.  Diabetes mellitus and Alzheimer's disease: shared pathology and treatment? , 2011, British journal of clinical pharmacology.

[3]  M. Shearman,et al.  The Intracellular Component of Cellular 3‐(4,5‐Dimethylthiazol‐2‐yl)‐2,5‐Diphenyltetrazolium Bromide (MTT) Reduction Is Specifically Inhibited by β‐Amyloid Peptides , 1995 .

[4]  A. Kapurniotu,et al.  Conformationally constrained human calcitonin (hCt) analogues reveal a critical role of sequence 17-21 for the oligomerization state and bioactivity of hCt. , 2002, European journal of biochemistry.

[5]  Aleksandra Velkova,et al.  Amyloid‐Kreuzwechselwirkung zur Inhibierung der Proteinaggregation, nicht aber der Proteinfunktion: Inhibierung der Insulinaggregation im nanomolaren Bereich durch ein IAPP‐Mimetikum , 2008 .

[6]  J. Bernhagen,et al.  Conformational transitions of islet amyloid polypeptide (IAPP) in amyloid formation in vitro. , 1999, Journal of molecular biology.

[7]  M. Nicolls,et al.  The clinical and biological relationship between Type II diabetes mellitus and Alzheimer's disease. , 2004, Current Alzheimer research.

[8]  J. Bernhagen,et al.  Amyloidogenicity of recombinant human pro-islet amyloid polypeptide (ProIAPP). , 2000, Chemistry & biology.

[9]  Y. Kozutsumi,et al.  Cholesterol-dependent Formation of GM1 Ganglioside-bound Amyloid β-Protein, an Endogenous Seed for Alzheimer Amyloid* , 2001, The Journal of Biological Chemistry.

[10]  M. Geyer,et al.  NMR Spectroscopic Investigation of Early Events in IAPP Amyloid Fibril Formation , 2009, Chembiochem : a European journal of chemical biology.

[11]  Li‐Mei Yan,et al.  Ein IAPP‐Mimetikum blockiert die zytotoxische Aggregation von Aβ – die Kreuzunterdrückung der Amyloidtoxizität von Aβ und IAPP deutet auf einen molekularen Zusammenhang zwischen Alzheimer‐Krankheit und Typ‐II‐Diabetes hin , 2007 .

[12]  C. Dobson Protein aggregation and its consequences for human disease. , 2006, Protein and peptide letters.

[13]  Ronald Wetzel,et al.  Seeding Specificity in Amyloid Growth Induced by Heterologous Fibrils* , 2004, Journal of Biological Chemistry.

[14]  Li‐Mei Yan,et al.  Hot‐Spot‐Regionen der Aβ‐IAPP‐Wechselwirkungsdomänen als hochaffine Bindungsstellen bei Kreuz‐ und Selbstassoziation , 2010 .

[15]  U Aebi,et al.  Amyloid fibril formation from full-length and fragments of amylin. , 2000, Journal of structural biology.

[16]  A. Kapurniotu,et al.  Design of a mimic of nonamyloidogenic and bioactive human islet amyloid polypeptide (IAPP) as nanomolar affinity inhibitor of IAPP cytotoxic fibrillogenesis , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Sharon Gilead,et al.  Identification and characterization of a novel molecular-recognition and self-assembly domain within the islet amyloid polypeptide. , 2002, Journal of molecular biology.

[18]  A. Kapurniotu,et al.  Exploiting cross-amyloid interactions to inhibit protein aggregation but not function: nanomolar affinity inhibition of insulin aggregation by an IAPP mimic. , 2008, Angewandte Chemie.

[19]  A. Kapurniotu,et al.  Amyloidogenicity and cytotoxicity of islet amyloid polypeptide. , 2001, Biopolymers.

[20]  L. Iversen,et al.  Inhibition of PC12 cell redox activity is a specific, early indicator of the mechanism of beta-amyloid-mediated cell death. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[21]  P. Westermark Aspects on human amyloid forms and their fibril polypeptides , 2005, The FEBS journal.

[22]  Ronald Frank,et al.  Identification of hot regions of the Abeta-IAPP interaction interface as high-affinity binding sites in both cross- and self-association. , 2010, Angewandte Chemie.

[23]  Christian Hölscher,et al.  Common pathological processes in Alzheimer disease and type 2 diabetes: A review , 2007, Brain Research Reviews.

[24]  A. Kapurniotu,et al.  IAPP mimic blocks Abeta cytotoxic self-assembly: cross-suppression of amyloid toxicity of Abeta and IAPP suggests a molecular link between Alzheimer's disease and type II diabetes. , 2007, Angewandte Chemie.

[25]  C. Behl,et al.  Amyloid peptides are toxic via a common oxidative mechanism. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[26]  G. Westermark,et al.  Inhibition of hIAPP amyloid-fibril formation and apoptotic cell death by a designed hIAPP amyloid- core-containing hexapeptide. , 2005, Chemistry & biology.

[27]  P E Fraser,et al.  Identification of a novel human islet amyloid polypeptide beta-sheet domain and factors influencing fibrillogenesis. , 2001, Journal of molecular biology.

[28]  Eva L. Feldman,et al.  How does diabetes accelerate Alzheimer disease pathology? , 2010, Nature Reviews Neurology.

[29]  H. Levine Quantification of beta-sheet amyloid fibril structures with thioflavin T. , 1999, Methods in enzymology.

[30]  David Eisenberg,et al.  Atomic structures of IAPP (amylin) fusions suggest a mechanism for fibrillation and the role of insulin in the process , 2009, Protein science : a publication of the Protein Society.

[31]  Fanling Meng,et al.  Combination of kinetically selected inhibitors in trans leads to highly effective inhibition of amyloid formation. , 2010, Journal of the American Chemical Society.